PET/CT in the assessment of previously treated skull base malignancies.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 19536771.
- Also identified by DOI 10.1002/hed.21147.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Altered anatomy, radiotherapy, hardware, and reconstructive materials distort the posttreatment ventral skull base. The diagnostic characteristics of positron emission tomography/CT (PET/CT) studies in those with suspected recurrent malignancy were assessed. A retrospective review was undertaken of patients with head and neck cancer who had PET/CT for ventral skull base disease. Thirty-four PET/CTs were performed for suspected recurrent malignancy in the skull base (mean age, 59.6 +/- 10.7 years; female 38%). The group comprised mainly minor salivary (35.3%), squamous (32.3%), and neuroectodermal (23.6%) tumors. Mean clinical follow-up after PET/CT was 256 +/- 173 days. Sensitivity was 100% but specificity was 40%. Standard uptake values (SUVs) for true positives were higher than for those without disease (p = .03). PET/CT is a highly sensitive test for malignant disease. The mucosal lining of the reconstructed skull base is a common source for inflammatory pathologies that may lead to false-positive PET/CT. Defining SUV thresholds for malignancy may improve specificity.
Medical subject headings
- Head and Neck Neoplasms
- Neoplasm Recurrence, Local
- Positron-Emission Tomography
- Skull Base
- Tomography, X-Ray Computed